Login / Signup
I recently posted the following thread on Twitter: I am so disappointed by the large number of pre-pandemic medical skeptics who have now turned into…
Thoughts about the use of the Win Ratio in Cardiovascular Outcome Trials
Cardiovascular trials often include non-fatal events (in addition to mortality) in their primary endpoints maintain the study power i.e., to capture enough events to detect…
Speculations on PARADISE-MI (sacubitril/valsartan post-MI) before the full results
Marc Pfeffer presented the results of PARADISE-MI at ACC last week. As discussed previously on CVCTCardiobrief, sacubitril/valsartan did not reduce the primary outcome compared to…
Wishful Thinking About Revascularization for Stable Coronary Artery Disease
A new meta-analysis concludes that revascularization for stable coronary artery disease has benefits over and above the benefits of medical therapy. But this may be wishful thinking.
LAA Closure During Heart Surgery – A Robust Positive Trial But What’s Next?
Richard Whitlock MD, PhD of McMaster University in Hamilton, Ontario presented the outcomes of the LAAOS III trial as a late breaking clinical trial (LBCT)…
Meet Spironolactone and Eplerenone’s Cardio-kidney Cousin, Finerenone
Spironolactone and eplerenone improve outcomes in heart failure. Finerenone is the newest mineralocorticoid receptor antagonist and is being tested for treatment of chronic kidney disease…
Preliminary Musings on PARADISE-MI (sacubitril-valsartan post MI)
Cardiologists have been happily prescribing angiotensin receptor neprilysin inhibitor, sacubitril-valsartan, for heart failure with reduced ejection (HFrEF) for a while now. And the drug was…
New Guidelines for Endpoints in Valve Intervention Trials: is it an autocracy?
“History has time and again shown that unlimited power in the hands of one person or group in most cases means that others are suppressed…
Athletes’ hearts after COVID: the entity that wasn’t
2020 was a year of relatively uninformative studies about the effects of COVID on the heart as I have previously lamented. 2021 has proved more…
Colchicine and COVID-19: a Tale of Two Trials
COLCORONA was a double-blinded randomised controlled trial of over 4000 patients comparing a 30 day course of colchicine with placebo for people with COVID-19 but…